Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
CAP-53194
AOB3834
CAS No: 660817-08-3
Chemical Name: N,1-Bis(4-nitrophenyl)-5-phenyl-1H-1,2,3-Triazole-4-carboxamide
98 Items
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $50.15 | Total: $250.75 |
| 1 | 10 | $42.48 | Total: $424.80 |
| 1 | 25 | $35.99 | Total: $899.75 |
| 1 | 50 | $30.68 | Total: $1,534.00 |
| 1 | 100 | $26.55 | Total: $2,655.00 |
Overview
Novel potent and selective Plk1 inhibitor
Chemical Properties
| Molecular Formula | C21H14N6O5 |
| Molecular Weight | 430.37 |
| CAS Numbers | 660817-08-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| IUPAC/Chemical Name | N,1-Bis(4-nitrophenyl)-5-phenyl-1H-1,2,3-Triazole-4-carboxamide |
| InChl Key | ORYIDPDQYDBZQA-UHFFFAOYSA-N |
| InChl Code | InChI=1S/C21H14N6O5/c28-21(22-15-6-8-17(9-7-15)26(29)30)19-20(14-4-2-1-3-5-14)25(24-23-19)16-10-12-18(13-11-16)27(31)32/h1-13H,(H,22,28) |
| SMILES Code | O=C(C1=C(C2=CC=CC=C2)N(C3=CC=C([N+]([O-])=O)C=C3)N=N1)NC4=CC=C([N+]([O-])=O)C=C4 |
Storage and Handling
0°C (short term), -20°C (long term), desiccated
Synonyms
CAP-53194; CAP 53194; CAP53194;
References
1) Shino N, Uchida T, Yoshida M, Nomura Y. Development and Assessment of a Nomogram to Propose the Initial Dosage Regimen of a Meropenem Infusion Based on Serum Creatinine and Age Using a Monte Carlo Simulation. Chem Pharm Bull (Tokyo). 2015;63(12):986-91.
2) Wang L, Kim M, Fang Q, Min J, Jeon WI, Lee SY, Son SJ, Joo SW, Lee SB. Hydrophobic end-gated silica nanotubes for intracellular glutathione-stimulated drug delivery in drug-resistant cancer cells. Chem Commun (Camb). 2013 Apr 21;49(31):3194-6.